Hapten Sciences, Inc.   Report issue

For profit Phase 1
Founded: Memphis TN United States (2010)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2016
NCT02700373
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Hapten Sciences, Inc.

Active Ingredients

Drugs in Phase 1 Trials (1)

pdc-apb (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dermatitis (Phase 1)

Dermatitis, Contact (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 1